4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kyverna Therapeutics, Inc. (KYTX) operates in the Biotechnology industry and is headquartered in EmeryVille, United States with about 129 employees. Its market capitalization is roughly $600 million. In the fiscal year ended 2025-12-31, KYTX reported $0M in revenue and ($161M) in net income.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $7M |
| Operating Income (EBIT) | ($170M) | ($143M) | ($62M) | ($29M) |
| Net Income | ($161M) | ($128M) | ($60M) | ($29M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($41M) | ($39M) | ($39M) | ($44M) | ($47M) |
| Net Income | ($40M) | ($38M) | ($37M) | ($42M) | ($45M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $294M | $305M | $75M | $67M | — |
| Total Liabilities | $62M | $38M | $207M | $141M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KYTX viewer.
About TickerBase · Data methodology & sources